Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups

T. Janáky, A. Juhász, S. Bajusz, V. Csernus, G. Srkalovic, L. Bokser, S. Milovanovic, T. W. Redding, Z. Rékási, A. Nagy, Andrew V Schally

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic radicals including an alkylating nitrogen mustard derivative of D-phenylalanine (D-melphalan), reactive cyclopropane, anthraquinone derivatives [2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine6 and D-ornithine6 or Nε-(2,3-diaminopropionyl)-0-lysine and A'*-(2,3-diaminopropionyl)-D-ornithine were used as carriers for one or two cytotoxic moieties. The enhanced biological activities produced by the incorporation of D amino acids into position 6 of the agonistic analogues were further increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with 10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues showed high affinities for the membrane receptors of human breast cancer cells, while the receptor binding affinities of peptides containing two cytotoxic side chains were lower. Antagonistic carriers [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,D-Lys6,D-Ala10]LH-RH [where Nal(2) is 3-(2-naphthyl)alanine], [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH, and their D-Pal(3)3 homologs [Pal(3) is 3-(3-pyridyl)alanine] as well as [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,Tyr 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH were linked to cytotoxic compounds. The hybrid molecules inhibited ovulation in rats at doses of 10 μg and suppressed LH release in vitro. The receptor binding of cytotoxic analogues was decreased compared to the precursor peptides, although analogues with 2-(hydroxymethyl)anthraquinone hemiglutarate had high affinities. All of the cytotoxic analogues tested inhibited [3H]thymidine incorporation into DNA in cultures of human breast and prostate cancer cell lines. Some cytotoxic analogues also significantly suppressed the growth of mammary and prostate cancers in vivo in animal models.

Original languageEnglish
Pages (from-to)972-976
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume89
Issue number3
StatePublished - Feb 1 1992
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Breast Neoplasms
Prostatic Neoplasms
Antimetabolites
Mechlorethamine
Anthraquinones
Peptides
Melphalan
Ornithine
Ovulation
Phenylalanine
Methotrexate
Antineoplastic Agents
Doxorubicin
Thymidine
Lysine
Animal Models
Anti-Bacterial Agents
Amino Acids
Cell Line

Keywords

  • Alkylating agents
  • Doxorubicin
  • Methotrexate
  • Receptor binding
  • Targeted chemotherapeutic agents

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. / Janáky, T.; Juhász, A.; Bajusz, S.; Csernus, V.; Srkalovic, G.; Bokser, L.; Milovanovic, S.; Redding, T. W.; Rékási, Z.; Nagy, A.; Schally, Andrew V.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, No. 3, 01.02.1992, p. 972-976.

Research output: Contribution to journalArticle

Janáky, T, Juhász, A, Bajusz, S, Csernus, V, Srkalovic, G, Bokser, L, Milovanovic, S, Redding, TW, Rékási, Z, Nagy, A & Schally, AV 1992, 'Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups', Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 3, pp. 972-976.
Janáky, T. ; Juhász, A. ; Bajusz, S. ; Csernus, V. ; Srkalovic, G. ; Bokser, L. ; Milovanovic, S. ; Redding, T. W. ; Rékási, Z. ; Nagy, A. ; Schally, Andrew V. / Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. In: Proceedings of the National Academy of Sciences of the United States of America. 1992 ; Vol. 89, No. 3. pp. 972-976.
@article{c0a53b4532974faf9802c29abb28840a,
title = "Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups",
abstract = "In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic radicals including an alkylating nitrogen mustard derivative of D-phenylalanine (D-melphalan), reactive cyclopropane, anthraquinone derivatives [2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine6 and D-ornithine6 or Nε-(2,3-diaminopropionyl)-0-lysine and A'*-(2,3-diaminopropionyl)-D-ornithine were used as carriers for one or two cytotoxic moieties. The enhanced biological activities produced by the incorporation of D amino acids into position 6 of the agonistic analogues were further increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with 10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues showed high affinities for the membrane receptors of human breast cancer cells, while the receptor binding affinities of peptides containing two cytotoxic side chains were lower. Antagonistic carriers [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,D-Lys6,D-Ala10]LH-RH [where Nal(2) is 3-(2-naphthyl)alanine], [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH, and their D-Pal(3)3 homologs [Pal(3) is 3-(3-pyridyl)alanine] as well as [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,Tyr 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH were linked to cytotoxic compounds. The hybrid molecules inhibited ovulation in rats at doses of 10 μg and suppressed LH release in vitro. The receptor binding of cytotoxic analogues was decreased compared to the precursor peptides, although analogues with 2-(hydroxymethyl)anthraquinone hemiglutarate had high affinities. All of the cytotoxic analogues tested inhibited [3H]thymidine incorporation into DNA in cultures of human breast and prostate cancer cell lines. Some cytotoxic analogues also significantly suppressed the growth of mammary and prostate cancers in vivo in animal models.",
keywords = "Alkylating agents, Doxorubicin, Methotrexate, Receptor binding, Targeted chemotherapeutic agents",
author = "T. Jan{\'a}ky and A. Juh{\'a}sz and S. Bajusz and V. Csernus and G. Srkalovic and L. Bokser and S. Milovanovic and Redding, {T. W.} and Z. R{\'e}k{\'a}si and A. Nagy and Schally, {Andrew V}",
year = "1992",
month = "2",
day = "1",
language = "English",
volume = "89",
pages = "972--976",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "3",

}

TY - JOUR

T1 - Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups

AU - Janáky, T.

AU - Juhász, A.

AU - Bajusz, S.

AU - Csernus, V.

AU - Srkalovic, G.

AU - Bokser, L.

AU - Milovanovic, S.

AU - Redding, T. W.

AU - Rékási, Z.

AU - Nagy, A.

AU - Schally, Andrew V

PY - 1992/2/1

Y1 - 1992/2/1

N2 - In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic radicals including an alkylating nitrogen mustard derivative of D-phenylalanine (D-melphalan), reactive cyclopropane, anthraquinone derivatives [2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine6 and D-ornithine6 or Nε-(2,3-diaminopropionyl)-0-lysine and A'*-(2,3-diaminopropionyl)-D-ornithine were used as carriers for one or two cytotoxic moieties. The enhanced biological activities produced by the incorporation of D amino acids into position 6 of the agonistic analogues were further increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with 10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues showed high affinities for the membrane receptors of human breast cancer cells, while the receptor binding affinities of peptides containing two cytotoxic side chains were lower. Antagonistic carriers [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,D-Lys6,D-Ala10]LH-RH [where Nal(2) is 3-(2-naphthyl)alanine], [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH, and their D-Pal(3)3 homologs [Pal(3) is 3-(3-pyridyl)alanine] as well as [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,Tyr 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH were linked to cytotoxic compounds. The hybrid molecules inhibited ovulation in rats at doses of 10 μg and suppressed LH release in vitro. The receptor binding of cytotoxic analogues was decreased compared to the precursor peptides, although analogues with 2-(hydroxymethyl)anthraquinone hemiglutarate had high affinities. All of the cytotoxic analogues tested inhibited [3H]thymidine incorporation into DNA in cultures of human breast and prostate cancer cell lines. Some cytotoxic analogues also significantly suppressed the growth of mammary and prostate cancers in vivo in animal models.

AB - In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic radicals including an alkylating nitrogen mustard derivative of D-phenylalanine (D-melphalan), reactive cyclopropane, anthraquinone derivatives [2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine6 and D-ornithine6 or Nε-(2,3-diaminopropionyl)-0-lysine and A'*-(2,3-diaminopropionyl)-D-ornithine were used as carriers for one or two cytotoxic moieties. The enhanced biological activities produced by the incorporation of D amino acids into position 6 of the agonistic analogues were further increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with 10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues showed high affinities for the membrane receptors of human breast cancer cells, while the receptor binding affinities of peptides containing two cytotoxic side chains were lower. Antagonistic carriers [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,D-Lys6,D-Ala10]LH-RH [where Nal(2) is 3-(2-naphthyl)alanine], [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH, and their D-Pal(3)3 homologs [Pal(3) is 3-(3-pyridyl)alanine] as well as [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,Tyr 5,Nε-(2,3-diaminopropionyl)-D-Lys 6,D-Ala10]LH-RH were linked to cytotoxic compounds. The hybrid molecules inhibited ovulation in rats at doses of 10 μg and suppressed LH release in vitro. The receptor binding of cytotoxic analogues was decreased compared to the precursor peptides, although analogues with 2-(hydroxymethyl)anthraquinone hemiglutarate had high affinities. All of the cytotoxic analogues tested inhibited [3H]thymidine incorporation into DNA in cultures of human breast and prostate cancer cell lines. Some cytotoxic analogues also significantly suppressed the growth of mammary and prostate cancers in vivo in animal models.

KW - Alkylating agents

KW - Doxorubicin

KW - Methotrexate

KW - Receptor binding

KW - Targeted chemotherapeutic agents

UR - http://www.scopus.com/inward/record.url?scp=0026503015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026503015&partnerID=8YFLogxK

M3 - Article

C2 - 1310542

AN - SCOPUS:0026503015

VL - 89

SP - 972

EP - 976

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 3

ER -